4CARD G L, ENGLAND B P, SUZUKI Y, et al. Struc- tural basis for the activity of drugs that inhibit phos- phodiesterases [ J ]. Structure, 2004, 12 ( 12 ) : 2233 - 2247.
5GIEMBYCZ M A. An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease [ J ]. British Journal of Clinical Pharmacology,2006,62 ( 2 ) : 138 - 152.
6GIEMBYCZ M A. Can the anti-inflammatory potential of PDE-4 inhibitors be realized:guarded optimism or wishful thinking? [J]. British Journal of Pharmacolo- gy ,2008,155 ( 3 ) :288 - 290.
8BICKSTON S J, SNIDER K R, KAPPUS M R. Teto- milast: new promise for phosphodiesterase-4 inhibi- tors? [J]. Drug Evaluations,2012,21 (12) : 1845 -1849.
9BEEH K M, BEIER J, LERCH C, et al. Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmat- ics and stable copd patients [ J ]. Lung, 2004,182 ( 6 ) : 369 - 377.
10TRALAU-STEWART C J, WILLIAMSON R A, NI- ALS A T, et al. GSK256066, an exceptionally high-af- finity and selective inhibitor of phosphodiesterase-4 suitable for administration by inhalation: in vitro, ki- netic, and in vivo characterization [ J ]. The Journal of Pharmacology and Experimental Therapeutics, 2011, 337(1) :145 - 154.
